IHC for SMARCA4 confirmed that these three SCLC-Y tumors harboring SMARCA4 mutations were SMARCA4-deficient, whereas SMARCA4 protein expression was retained in all other tumors (Fig. 3; Supplementary Table S2). This evidence concerns the gene SMARCA4 and small cell lung carcinoma.